Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

What Was Tested

Researchers studied Insulin Aspart and Insulin Detemir in this randomized controlled trial publication.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

After an 8-week run-in, subjects were randomized (1:1:1) to double-blind mealtime faster aspart (n = 381), IAsp (n = 380), or open-label postmeal faster aspart (n = 382)-each with insulin detemir.

How the Study Was Run

In design terms this was a randomized, double-blind, open-label and multicenter study.

The participants were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

As a double-blind Insulin Aspart study, the assignments were hidden from both participants and investigators until the end.

Everyone knew when Insulin Aspart was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Running at several centres spread the Insulin Aspart study over different clinics and patient groups.

The timeline in the abstract includes 26 weeks.

The primary end point was change from baseline in HbA1c after 26 weeks.

What Was Measured

The subject headings attached to it are Blood Glucose, Body Mass Index, Diabetes Mellitus, Type 1, Endpoint Determination, Glycated Hemoglobin, Hypoglycemia and Insulin Aspart.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Insulin Aspart and Insulin Detemir over 26 weeks.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Diabetes care), a journal based in United States.

More context: the Insulin Aspart compound page and the Insulin Detemir compound page.